Nilofer Noorie, M (2021) A Comparative study of Efficacy & Safety Profile of Acetyl-L-Carnitine as Add on Therapy in the Treatment of Depression. Masters thesis, (2018-2019) Kilpauk Medical College, Chennai.
|
Text
200600421nilofer_noorie.pdf Download (2MB) | Preview |
Abstract
INTRODUCTION: Depression is one of the largest silent epidemics worldwide and it is a compelling public health concern. It is one of the major causes of disability with more than 264 million people affected worldwide. Two-thirds of patients do not achieve full remission on current available antidepressants and the therapeutic effect is seen only after 2-3 weeks of antidepressant. Only few clinical trials that have proved the efficacy of ALCAR as a rapid acting anti depressant. Hence, this study is undertaken as an open label prospective interventional study to assess the therapeutic effect of ALCAR as an add-on therapy to SSRIs in the treatment of Depression and its effectiveness in reducing the latency period of anti depressant effect. AIM AND OBJECTIVES: 1. To study the efficacy of Acetyl L-Carnitine as an add-on therapy in the treatment of depression as compared to the standard treatment. 2. To assess and compare the latency period with acetyl- carinitine as an add on therapy with anti depressants. 3. To study the safety profile of Acetyl L-Carnitine METHODOLOGY: This was a Prospective, open label, randomized controlled study conducted at Department of pharmacology Government Kilpauk Medical College. A total of 62 patients diagnosed with depression by MADRS score were included in the study and they were randomized into two groups of control who received standard treatment and study group who received standard treatment along with Acetl-L-Carnitine as an add on for 3 months. RESULTS: There was a significant mean reduction in MADRS score in both ALCAR and control group when compared to baseline at 4th ,8th and 12 th week. However there was higher reduction of MADRS score at 1st week in ALCAR group when compared to the control group. (p value<0.001). The latency period was reduced to one week in ALCAR group when compared to control group which showed 2 week for therapeutic response. CONCLUSION: From this study we conclude that, Acetyl-L-Carnitine at dose of 1gram/day as an add on therapy with SSRIs is effective in improving the overall symptoms of Depression.It causes rapid onset of Antidepressant effect by reducing the latency period. Further studies are needed to explore the long term efficacy of Acetyl-L-Carnitine in the treatment of Depression.
| Item Type: | Thesis (Masters) |
|---|---|
| Additional Information: | 201816151 |
| Uncontrolled Keywords: | Depression, Acetyl-L-Carnitine, Montgomery Asberg Depression Rating (MADRS) score. |
| Subjects: | MEDICAL > Pharmacology |
| Depositing User: | Subramani R |
| Date Deposited: | 11 May 2021 16:41 |
| Last Modified: | 09 Jan 2022 16:44 |
| URI: | http://repository-tnmgrmu.ac.in/id/eprint/16482 |
Actions (login required)
 |
View Item |
